Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus ERYTHROMYCIN AND BENZOYL PEROXIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus ERYTHROMYCIN AND BENZOYL PEROXIDE.
E.E.S. 200 vs ERYTHROMYCIN AND BENZOYL PEROXIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
Erythromycin is a macrolide antibiotic that acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. Benzoyl peroxide has bactericidal effects against Propionibacterium acnes, likely through the release of free radical oxygen that oxidizes bacterial proteins. It also has keratolytic and comedolytic properties.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
Topical: Apply a thin layer to affected areas once daily in the evening.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
Erythromycin: 1.4–2.0 hours (terminal half-life in adults). Benzoyl peroxide: Not applicable; it is a topical agent with negligible systemic absorption.
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Erythromycin is primarily excreted via bile (fecal elimination) with approximately 15% excreted unchanged in urine. Benzoyl peroxide is degraded to benzoic acid, which is conjugated with glycine to form hippuric acid and excreted renally; less than 5% is excreted unchanged in urine.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic